The strong association of Gal-3 with the onset of AD and the prominent effects of Gal-3 on microglia in response to neuroinflammation suggest that Gal-3 inhibition for therapeutic purposes is an innovative and interesting strategy, although further clinical investigations are needed to clarify the potential for AD prevention. This evidence concerns the gene LGALS3 and Alzheimer disease.